Yahoo Finance: Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis ...
Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1Haemoglobin response was superior with etavopivat: ...
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis ...
News Medical: Inappropriate triage prolongs time to pain medication in vaso-occlusive crisis
Most individuals living with sickle cell disease who presented to the emergency department with a pain crisis, known as vaso-occlusive crisis (VOC), were not triaged appropriately according to ...
The analysis included 66 visits: 23 and 43 visits were assigned emergency severity index 2 and 3. HealthDay News — A majority of patients with sickle cell disease (SCD) with vaso-occlusive crisis (VOC ...
Topline data for the once-daily PKR activator etavopivat demonstrate a 27% reduction in vaso-occlusive crises and a robust hematologic response in patients with SCD.
Healio: Analgesia for sickle cell vaso-occlusive crises often delayed due to improper ED triage
Please provide your email address to receive an email when new articles are posted on . Patients with sickle cell disease who have vaso-occlusive crises often get delayed treatment in ED due to ...
Analgesia for sickle cell vaso-occlusive crises often delayed due to improper ED triage
The American Journal of Managed Care: Adverse Effects of Hospitalization for Vaso-Occlusive Crises Persist for 12 Months
Children with sickle cell disease who require hospitalization for vaso-occlusive crises can experience adverse effects for up to 12 months following hospitalization, a study found. SCD affects ...